1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Sri Lanka Pharmaceuticals and Healthcare Report Q2 2016

Sri Lanka Pharmaceuticals and Healthcare Report Q2 2016

  • March 2016
  • -
  • Business Monitor International
  • -
  • 69 pages

Includes 3 FREE quarterly updates

BMI View: Domestic generic drugmakers will be at a distinct advantage under Sri Lanka's proposednational medicinal policy. With directives boosting generic drug sales through generic substitution, localpharmaceutical companies will be further assisted as the government aims to use the policy to reducemedicine imports. We highlight that these changes will come at the expense of drugmakers in India andBangladesh, which have been a key source of pharmaceutical imports into Sri Lanka.

Headline Expenditure Projections

- Pharmaceuticals: LKR82.88bn (USD609mn) in 2015 to LKR90.57bn (USD612mn) in 2016.

- Healthcare: LKR308.39bn (USD2.27bn) in 2015 to LKR335.42bn (USD2.26bn) in 2016.

Table Of Contents

Sri Lanka Pharmaceuticals and Healthcare Report Q2 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Sri Lanka 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Sri Lanka 2012-2020) 12
Healthcare Market Forecast 13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Sri Lanka 2012-2020) 15
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Sri Lanka 2012-2020) 15
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Sri Lanka 2012-2020) 16
Prescription Drug Market Forecast 16
Pharmaceutical Trade Forecast 18
Table: Pharmaceutical Trade Data And Forecasts (Sri Lanka 2014-2020) 20
Table: Pharmaceutical Trade Data And Forecasts local currency (Sri Lanka 2014-2020) 20
Industry Risk Reward Indices 21
Asia Pacific Risk/Reward Index 21
Sri Lanka - Risk/Reward Index 27
Rewards 27
Risks 27
Regulatory Review 28
Intellectual Property Issues 31
Pricing And Reimbursement Regimes 32
Market Overview 34
Healthcare Sector 34
Clinical Trials 38
Epidemiology 39
Competitive Landscape 45
Research-Based Industry 45
Table: Multinational Market Activity 46
Pharmaceutical Distribution 47
Pharmaceutical Retail Sector 48
Company Profile 49
GlaxoSmithKline 49
Hemas Holdings 52
State Pharmaceuticals Corporation (SPC) 55
Demographic Forecast 58
Demographic Outlook 58
Table: Population Headline Indicators (Sri Lanka 1990-2025) 59
Table: Key Population Ratios (Sri Lanka 1990-2025) 59
Table: Urban/Rural Population and Life Expectancy (Sri Lanka 1990-2025) 60
Table: Population By Age Group (Sri Lanka 1990-2025) 60
Table: Population By Age Group % (Sri Lanka 1990-2025) 61
Glossary 63
Methodology 65
Pharmaceutical Expenditure Forecast Model 65
Healthcare Expenditure Forecast Model 65
Notes On Methodology 66
Risk/Reward Index Methodology 67
Index Overview 68
Table: Pharmaceutical Risk/Reward Index Indicators 68
Indicator Weightings 69

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.